TARGET AUDIENCE
This program is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, surgeons and other allied healthcare professionals involved in the treatment of melanoma and nonmelanoma skin cancers.

LEARNING OBJECTIVES

• Identify factors affecting the risk of recurrence for early-stage melanoma, and evaluate the role of approved targeted and immunotherapeutic agents as adjuvant therapy.
• Use clinical trial evidence to safely and effectively incorporate immunotherapeutic, targeted or combination approaches into the management of newly diagnosed metastatic melanoma.
• Consider age, performance status and other biological and disease-related factors in the selection of therapy, including potential clinical trial participation, for patients with metastatic melanoma who progress on front-line immune checkpoint inhibitor-based treatment.
• Assess efficacy and safety findings with anti-LAG-3 antibodies in combination with anti-PD-1/PD-L1 antibodies for advanced melanoma in order to optimally integrate this strategy into the treatment armamentarium.
• Review available data with investigational strategies currently undergoing evaluation for early and advanced melanoma, and refer appropriate patients for trial participation.
• Use clinical trial evidence to safely and effectively integrate immunotherapeutic approaches into the management of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).
• Formulate a long-term clinical plan for the management of locally advanced or metastatic basal cell carcinoma (BCC), incorporating targeted and immunotherapeutic strategies.
• Assess the rationale for and clinical trial data with anti-PD-1/PD-L1 antibodies for Merkel cell carcinoma (MCC), and optimally employ available agents in patient care.
• Evaluate clinical research findings with targeted and immunotherapeutic agents as neoadjuvant or adjuvant therapy for cSCC, BCC or MCC to determine the current clinical utility of various approaches.
• Recall the design of ongoing clinical trials evaluating novel agents and strategies for cSCC, BCC and MCC, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Presentations Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Omid Hamid, MD
Chief of Research/Immuno-Oncology
Co-Director, Cutaneous Malignancy Program
The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
Los Angeles, California

Advisory Committee and Consulting Agreements: Alkermes, Amgen Inc, Bactonix, BeiGene Ltd, BioAtla, Bristol Myers Squibb, Eisai Inc, Genentech, a member of the Roche Group, Georgiamune, GigaGen, GSK, Grit Bio, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Instil Bio, IO Biotech, Iovance Biotherapeutics, Janssen Biotech Inc, KSQ Therapeutics, Merck, Moderna, Novartis, Obsidian Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Tempus, Zelluna Immunotherapy AS; Contracted Research: Akeso Inc, Amgen Inc, Arcus Biosciences, BioAtla, Bristol Myers Squibb, Chinook Therapeutics, CytomX Therapeutics, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Iovance Biotherapeutics, Merck, Merck Serono, Moderna, NextCure, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Seagen Inc, Zelluna Immunotherapy AS; Speakers Bureau: Bristol Myers Squibb, Immunocore, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationship: Vial.

Evan J Lipson, MD
Associate Professor, Medical Oncology
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Advisory Committee: Bristol Myers Squibb, CareDx, Eisai Inc, HUYA Bioscience International, Immunocore, Instil Bio, Merck, Nektar, Novartis, OncoSec Medical, Pfizer Inc, Rain Oncology, Regeneron Pharmaceuticals Inc, Replimune, Sanofi.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Regeneron Pharmaceuticals Inc.

Release date: August 2023
Expiration date: August 2024